Vol 12, No 5 (2011): Practical Diabetology
Review article
Published online: 2011-12-29
Bromokryptyna — stary lek w nowej formule skutecznym sposobem leczenia cukrzycy typu 2
Diabetologia Praktyczna 2011;12(5):175-179.
Abstract
Quick-release bromocriptine mesylate was approved
by the Food and Drug Administration (FDA) in May
2009, for the treatment of type 2 diabetes (T2DM).
The quick-release formulation of bromocriptine (bromocriptine-
QR; Cycloset) represents a novel therapeutic
option in T2DM by targeting centrally mediated
pathways of glucose metabolism, effecting in
reducing plasma glucose, triglycerides, free fatty acid
(FFA) levels and eventually cardiovascular events.
Randomized controlled trials have shown that bromocriptine-
QR lowers glycated hemoglobin by 0.4–
–0.8% either as monotherapy or in combination with
other anti-diabetes medications. Bromocriptine-QR
mechanism of action, unique formulation, clinical
efficacy and safety, proves it to be a great alternative
to current treatments for type 2 diabetes. (Diabet.
Prakt. 2011; 12, 5: 175–179)
Keywords: bromocriptinequick release formulationdiabetesinsulin resistancecardiovascular risk